Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

DeepGRAI (Deep Gray Rating via Artificial Intelligence) Provides Feasible and Clinically Meaningful Thalamic Volume Measurement on Multi-Center Clinical-Quality T2-FLAIR Images
Multiple Sclerosis
P12 - Poster Session 12 (5:30 PM-6:30 PM)
12-009

 The thalamus is a key gray matter structure, and a sensitive marker of neurodegeneration in MS. Previous reports have indicated that thalamic volumetry using AI on clinical-quality T2-FLAIR images alone, is fast and reliable. 

To investigate the feasibility and clinical validity of thalamic volume (TV) measurement using artificial intelligence (AI) based on routine clinical scans from patients with multiple sclerosis (MS), in a large multi-center study.

DeepGRAI (Deep Gray Rating via Artificial Intelligence) is a multi-center (30 USA sites), longitudinal, observational, retrospective, real-word, registry study of relapsing-remitting (RR) MS patients. Brain MRI exams acquired at baseline and follow-up on 1.5T or 3T scanners with no prior standardization were collected to resemble real-world situations. Thalamic volume measurement was performed on T2-FLAIR using the DeepGRAI tool, and on 2 dimensional (D)- and 3D T1-weighted image (WI) by using FIRST software.

1,002 RRMS patients were followed for an average of 2.6 years. Each center enrolled between 30-35 RRMS patients. The longitudinal thalamic volume analysis was feasible in 96.1% of patients based on T2-FLAIR, 61.8% on 2D-T1-WI and 33.3% on 3D-T1-WI. Over the follow-up, new T2-lesion volume (LV) (p=0.005) and TV (p=0.045) were significantly different between disability progression (DP), stable and disability improvement (DI) patient populations. There were no significant differences for 2D- and 3D-T1-WI TV analyses between DP, DI and Stable patients. In the binary logistic regression model that included age, sex, disease duration, EDSS, and time of follow-up, the presence of DP was significantly predicted by time to follow-up in months (p=0.001) and TV % change (p-value=0.017). Despite differences in MRI scanner model, software or protocol, DP MS patients had greater TV % change on T2-FLAIR sequence than non-DP (-2.0 vs. -0.4, p=0.007).

DeepGRAI provides feasible and clinically meaningful thalamic volume measurement on multi-center, clinical-quality T2-FLAIR images in the real-word setting. 

Authors/Disclosures
Robert Zivadinov, MD, PhD, FAAN (Buffalo Neuroimaging Analysis Center)
PRESENTER
The institution of Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Filterlex. Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for 3D Communications. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Omnicuris. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurology Live. The institution of Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen.
Niels Bergsland (Buffalo Neuroimaging Analysis Center / State University of New York At Buffalo) Prof. Bergsland has nothing to disclose.
Dejan Jakimovski, MD, PhD (Buffalo Neuroimaging Analysis Center, University at Buffalo) Dr. Jakimovski has nothing to disclose.
Bianca Weinstock-Guttman, MD (Department of Neurology, University At Buffalo) Dr. Weinstock-Guttman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme &Sanofi. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving as a Reviewer with NIH.
Ralph H. Benedict, PhD (University At Buffalo) Dr. Benedict has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Benedict has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Roche. Dr. Benedict has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Benedict has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Benedict has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Meyers Squibb. Dr. Benedict has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Benedict has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Benedict has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Brystal Mier Squibb. Dr. Benedict has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for EMD Serono. The institution of Dr. Benedict has received research support from Genzyme. The institution of Dr. Benedict has received research support from Biogen. The institution of Dr. Benedict has received research support from Bristol Myer Squib. Dr. Benedict has received intellectual property interests from a discovery or technology relating to health care.
Jon V. Riolo, PhD Dr. Riolo has received personal compensation for serving as an employee of Bristol Myers Squib.
Diego Silva (Bristol-Myers Squibb Company) Diego Silva has received personal compensation for serving as an employee of BMS. Diego Silva has received stock or an ownership interest from BMS.
Michael G. Dwyer III, MD, PhD (Buffalo Neurological Analysis Center) Dr. Dwyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Keystone Heart, Ltd. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Dwyer has received research support from Novartis. The institution of Dr. Dwyer has received research support from Keystone Heart, Ltd. The institution of Dr. Dwyer has received research support from Bristol Myers Squibb. The institution of Dr. Dwyer has received research support from Roche.